Preclinical Pharmacodynamic and Pharmacokinetic Profiling Services
At Ace Therapeutics, we bridge the gap between Alzheimer's disease (AD) drug discovery and successful preclinical advancement. Our pharmacodynamic and pharmacokinetic profiling services are designed to unravel how your candidates interact with complex AD pathology—from amyloid-beta plaques and tau tangles to neuroinflammation—ensuring they achieve the right exposure, at the right target, for the right duration.
AD therapeutics face dual challenges of crossing the blood-brain barrier (BBB) and engaging dynamic, often aggregation-prone targets. Poor PK/PD correlations account for nearly 40% of preclinical attrition. Our solutions address these hurdles by
Quantify drug distribution and clearance across AD-relevant compartments.
Connect exposure to therapeutic effect with disease-specific endpoints.
Accelerate candidate optimization with predictive tools.
Minimize translational risks with cross-species insights.
To address the multifaceted nature of Alzheimer's R&D, we deploy innovative platforms.
| Technology | Application |
| 3D neurospheroid models | Mimic AD-specific protein aggregation for real-time PD monitoring. |
| CRISPR-edited organoids | Study ApoE genotype-dependent PK variability. |
| PET imaging surrogate markers | Track target engagement in rodent brains (e.g., tau fibril binding). |
| Single-cell RNA-seq | Elucidate PD mechanisms in microglia and neurons. |
In Alzheimer's research, robust PK/PD data isn't just a checkbox—it's the foundation of translational success. Let Ace Therapeutics equip you with the insights to advance candidates with confidence. Contact us today to design a preclinical strategy as unique as your science.
How do you address species differences in Aβ clearance rates
We perform parallel studies in humanized models (e.g., transgenic mice with humanized Aβ sequences) and apply scaling algorithms to refine human PK predictions.
Can you profile biologics like anti-tau antibodies
Yes. Our platforms include receptor occupancy assays and CSF PK sampling tailored for large molecules.
What biomarkers do you track for neuroinflammation PD studies
We measure GFAP (astrocytes), IBA1 (microglia), and cytokines (e.g., IL-6, TNF-α) in brain tissue and CSF.
How much compound is required for PK/PD screening
Most assays require 5–10 mg for small molecules or 1–2 mg for biologics. Microsampling reduces material needs.
What turnaround times can I expect
Standard PK profiling takes 3–4 weeks. Complex PD studies (e.g., 3D neurospheroids) require 8–10 weeks.
Our products and services are for research use only and can not be used for diagnostic or other purposes.
Make Order
Experimental Scheme
Implementation
Conclusion
Ace Therapeutics is a specialized team of scientists and technical professionals committed to working closely with clients worldwide. We offer comprehensive preclinical testing solutions to support the development of novel therapies and medications across a range of disease areas.
Ace Therapeutics boasts a team of highly committed and skilled researchers dedicated to delivering innovative preclinical contract research solutions.
We provide tailored preclinical services designed to streamline your research process and advance promising concepts into actionable insights, ensuring efficient progress in drug development.